Canada markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.870.00 (0.00%)
At close: 04:00PM EDT

Amryt Pharma plc

45 Mespil Road
Dublin 4
353 1 518 0200

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees289

Key Executives

NameTitlePayExercisedYear Born
Dr. Joseph A. WileyCEO & Director1.65MN/A1971
Mr. Rory P. NealonCFO, COO & Company Sec.890kN/A1968
Ms. Elizabeth Varki Jobes J.D.Sr. VP & Global Chief Compliance OfficerN/AN/A1967
Mr. John McEvoyGen. CounselN/AN/AN/A
Mr. Stephen JoyceSr. VP, Global Head of Marketing & Corp. Comms. and Head of APACN/AN/AN/A
Ms. Julie EastwoodHead of HRN/AN/AN/A
Ms. Derval O'CarrollHead of Regulatory AffairsN/AN/AN/A
Mr. Gerry GilliganHead of Manufacturing Supply ChainN/AN/AN/A
Dr. Helen PhillipsHead of Medical AffairsN/AN/AN/A
Ms. Sheila M. FramePres of AmericasN/AN/A1962
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Corporate Governance

Amryt Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.